<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232739</url>
  </required_header>
  <id_info>
    <org_study_id>P03-6320</org_study_id>
    <nct_id>NCT00232739</nct_id>
  </id_info>
  <brief_title>Study of the 2.25mm Sirolimus-Eluting Stent in the Treatment of Patients With Coronary Artery Lesions</brief_title>
  <official_title>A Multicenter, Non-Randomized Study of the 2.25mm Sirolimus-Eluting BX VELOCITYTM Balloon-Expandable Stent in the Treatment of Patients With de Novo Native Coronary Artery Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the safety and effectiveness of the
      sirolimus-eluting Bx VELOCITYTM stent in reducing in-lesion restenosis in patients with de
      novo native coronary artery lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter (approximately 10 - 14 sites), prospective, non-randomized study. The
      study is designed to evaluate the safety and effectiveness of the sirolimus-eluting Bx
      VELOCITYTM stent in patients with de novo native coronary artery lesions. A total of 100
      patients will be entered in the study. Patients who meet the eligibility criteria will be
      enrolled into the study. Patients will be followed at 30 days, 6, 9, and 12 months, and at 2,
      3, 4 and 5 years post-procedure, with all patients undergoing repeat angiography at 6 months.
      Approximately 50 patients will be required to have an intravascular ultrasound (IVUS)
      procedure at baseline and at the 6-month angiographic follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure</measure>
    <time_frame>From post-procedure to 6 months</time_frame>
    <description>In-lesion restenosis was defined as over 50 percent diameter stenosis either within the stented segment or within 5 mm proximal or distal to the stent edges at a qualifying follow-up angiogram.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Percentages of Participants Who Experienced Any Major Adverse Cardiac Events up to Each Scheduled Follow-up</measure>
    <time_frame>From post-procedure to 4 years</time_frame>
    <description>The percentages are cumulative up to each of the scheduled post-procedure follow-up: 30 days, 6, 9, and 12 months, and 2, 3, 4 and 5 years. Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Experienced Any Angiographic In-stent Binary Restenosis up to 6 Months Post-procedure.</measure>
    <time_frame>From post-procedure to 6 months</time_frame>
    <description>In-stent restenosis was defined as greater than or equal 50 percent diameter stenosis within the stented segment at a qualifying follow-up angiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average In-stent and In-lesion Minimum Lesion Diameters (MLD) at 6 Months Post-procedure.</measure>
    <time_frame>From post-procedure to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Percentages of Participants Who Experienced Any Target Lesion Revascularization (TLR) up to 6 and 9 Months Post-procedure.</measure>
    <time_frame>From post-procedure to 6 months and 9 months</time_frame>
    <description>TLR was defined as any &quot;clinically-driven&quot; repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Percentages of Participants Who Experienced Any Target Vessel Revascularization (TVR) up to 6 and 9 Months Post-procedure.</measure>
    <time_frame>From post-procedure to 6 months and 9 months follow-up</time_frame>
    <description>TVR was defined as any clinically driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations were those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis being greater than or equal to 50 percent measured by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Percentages of Participants Who Experienced Any Target Vessel Failure (TVF) up to 6 and 9 Months Post-procedure</measure>
    <time_frame>From post-procedure to 6 months and 9 months follow-up</time_frame>
    <description>TVF was defined as any Target vessel revascularization, Q wave or non-Q wave MI, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Lumen Volume (mm3) at Post-procedure</measure>
    <time_frame>At Post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Stent Obstruction Volume at Post-procedure</measure>
    <time_frame>At post-procedure</time_frame>
    <description>Stent obstruction Volume equals 100 * [1-(lumen volume/baseline stent volume)]; usually this is equal to zero at baseline, since the stent is freshly implanted and no obstruction is expected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Lumen Volume (mm3) at 6 Months Post-procedure</measure>
    <time_frame>From post-procedure to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Stent Obstruction Volume at 6 Months Post-procedure</measure>
    <time_frame>From post-procedure to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Lesion Success at Post-procedure</measure>
    <time_frame>At post-procedure</time_frame>
    <description>Lesion success defined as the attainment of &lt;50 percent residual stenosis (by QCA) using any percutaneous method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Device Success at Post-procedure</measure>
    <time_frame>At post-procedure</time_frame>
    <description>Device success was defined as achievement of a final residual diameter stenosis of less than 50 percent as measured by QCA, using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Procedure Success Before Hospital Discharge</measure>
    <time_frame>From post-procedure to hospital discharge</time_frame>
    <description>Procedure success defined as achievement of a final diameter stenosis of less than 50 percent (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CYPHER Sirolimus-eluting Coronary Stent</intervention_name>
    <description>2.25 Cypher Sirolimus-eluting Coronary Stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female patients minimum 18 years of age

          2. Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society
             Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald
             Classification B&amp;C, I-II) OR patients with documented silent ischemia;

          3. Target lesion is 20mm in length (visual estimate);

          4. Target lesion stenosis is &gt;50% and &lt;100% (visual estimate);

        Exclusion Criteria:

          1. Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented
             total CK &gt;2 times normal within the preceding 24 hours and the CK and CK-MB enzymes
             remains above normal at the time of treatment;

          2. Has unstable angina classified as Braunwald III B or C, or is having a peri
             infarction;

          3. Documented Left ventricular ejection fraction 25%;

          4. Impaired renal function (creatinine &gt; 3.0 mg/dl) at the time of treatment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sriram Iyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lenox Hill Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Moses JW, Nikolsky E, Mehran R, Cambier PA, Bachinsky WB, Leya F, Kuntz RE, Popma JJ, Schleckser P, Wang H, Cohen SA, Leon MB; SIRIUS 2.25 Investigators. Safety and efficacy of the 2.25-mm sirolimus-eluting Bx Velocity stent in the treatment of patients with de novo native coronary artery lesions: the SIRIUS 2.25 trial. Am J Cardiol. 2006 Dec 1;98(11):1455-60. Epub 2006 Oct 13.</citation>
    <PMID>17126649</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <results_first_submitted>October 19, 2009</results_first_submitted>
  <results_first_submitted_qc>January 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 8, 2010</results_first_posted>
  <last_update_submitted>March 11, 2010</last_update_submitted>
  <last_update_submitted_qc>March 11, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Sriram Iyer, MD</name_title>
    <organization>Lenox Hill Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
          <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
          <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.4" spread="9.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="30.3" upper_limit="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Myocardial Infarction (MI)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>History of MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="25.5" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without History of MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N/A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure</title>
        <description>In-lesion restenosis was defined as over 50 percent diameter stenosis either within the stented segment or within 5 mm proximal or distal to the stent edges at a qualifying follow-up angiogram.</description>
        <time_frame>From post-procedure to 6 months</time_frame>
        <population>The number of participants with six months follow up and non-missing six months binary angiographic restenosis (BAR) results.</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure</title>
          <description>In-lesion restenosis was defined as over 50 percent diameter stenosis either within the stented segment or within 5 mm proximal or distal to the stent edges at a qualifying follow-up angiogram.</description>
          <population>The number of participants with six months follow up and non-missing six months binary angiographic restenosis (BAR) results.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="9.3" upper_limit="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Historical control groups consist of propensity-scored matched cohorts (100 patients each, based on Reference Vessel Diameter, lesion length, diabetes, left anterior artery diseased vessel, and gender) of plain old balloon angioplasty (POBA), first generation (Palmaz-Schatz) bare metal stent (BMS1), and BX VELOCITY bare metal stent (BMS2). Study showed the risk of 6-month in-lesion binary angiographic restenosis (BAR) was much lower for the 2.25 Sirolimus stent compared with POBA, BMS1 or BMS2.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Primary analysis posterior probability</param_type>
            <param_value>0.9926</param_value>
            <estimate_desc>Secondary analysis for comparing Sirolimus stent with BMS1 and BMS2 signified that Sirolimus stent is superior to POBA, BMS1 and BMS2 in reducing the BAR risk.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Percentages of Participants Who Experienced Any Major Adverse Cardiac Events up to Each Scheduled Follow-up</title>
        <description>The percentages are cumulative up to each of the scheduled post-procedure follow-up: 30 days, 6, 9, and 12 months, and 2, 3, 4 and 5 years. Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
        <time_frame>From post-procedure to 4 years</time_frame>
        <population>The number of participants who had four years post-procedure follow up or who had at least one event prior to the end of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percentages of Participants Who Experienced Any Major Adverse Cardiac Events up to Each Scheduled Follow-up</title>
          <description>The percentages are cumulative up to each of the scheduled post-procedure follow-up: 30 days, 6, 9, and 12 months, and 2, 3, 4 and 5 years. Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).</description>
          <population>The number of participants who had four years post-procedure follow up or who had at least one event prior to the end of follow-up.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="2.7" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="3.3" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="4.9" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Years Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="9.6" upper_limit="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Years Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" lower_limit="13.0" upper_limit="29.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Years Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="18.2" upper_limit="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Experienced Any Angiographic In-stent Binary Restenosis up to 6 Months Post-procedure.</title>
        <description>In-stent restenosis was defined as greater than or equal 50 percent diameter stenosis within the stented segment at a qualifying follow-up angiogram.</description>
        <time_frame>From post-procedure to 6 months</time_frame>
        <population>The number of participants with six months follow up and non-missing six months binary angiographic restenosis results.</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Any Angiographic In-stent Binary Restenosis up to 6 Months Post-procedure.</title>
          <description>In-stent restenosis was defined as greater than or equal 50 percent diameter stenosis within the stented segment at a qualifying follow-up angiogram.</description>
          <population>The number of participants with six months follow up and non-missing six months binary angiographic restenosis results.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="5.5" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average In-stent and In-lesion Minimum Lesion Diameters (MLD) at 6 Months Post-procedure.</title>
        <time_frame>From post-procedure to 6 months</time_frame>
        <population>The number of participants with six months follow up and non-missing six months binary angiographic restenosis results.</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Average In-stent and In-lesion Minimum Lesion Diameters (MLD) at 6 Months Post-procedure.</title>
          <population>The number of participants with six months follow up and non-missing six months binary angiographic restenosis results.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Average In-stent MLD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Average In-lesion MLD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.35" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Percentages of Participants Who Experienced Any Target Lesion Revascularization (TLR) up to 6 and 9 Months Post-procedure.</title>
        <description>TLR was defined as any “clinically-driven” repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel.</description>
        <time_frame>From post-procedure to 6 months and 9 months</time_frame>
        <population>The number of participants who had sufficient follow-up or who had an event prior to the end of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percentages of Participants Who Experienced Any Target Lesion Revascularization (TLR) up to 6 and 9 Months Post-procedure.</title>
          <description>TLR was defined as any “clinically-driven” repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel.</description>
          <population>The number of participants who had sufficient follow-up or who had an event prior to the end of follow-up.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" lower_limit="0.8" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="1.2" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Percentages of Participants Who Experienced Any Target Vessel Revascularization (TVR) up to 6 and 9 Months Post-procedure.</title>
        <description>TVR was defined as any clinically driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations were those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis being greater than or equal to 50 percent measured by QCA.</description>
        <time_frame>From post-procedure to 6 months and 9 months follow-up</time_frame>
        <population>The number of participants who had sufficient 9 months post-procedure follow-up or had the event prior to 9 months.</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percentages of Participants Who Experienced Any Target Vessel Revascularization (TVR) up to 6 and 9 Months Post-procedure.</title>
          <description>TVR was defined as any clinically driven repeat percutaneous intervention of the target vessel or bypass surgery of the target vessel. Clinically-driven revascularizations were those in which the patient has a positive functional study, ischemic ECG changes at rest in a distribution consistent with the target vessel, or ischemic symptoms, and an in-lesion diameter stenosis being greater than or equal to 50 percent measured by QCA.</description>
          <population>The number of participants who had sufficient 9 months post-procedure follow-up or had the event prior to 9 months.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="2.8" upper_limit="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="4.2" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Percentages of Participants Who Experienced Any Target Vessel Failure (TVF) up to 6 and 9 Months Post-procedure</title>
        <description>TVF was defined as any Target vessel revascularization, Q wave or non-Q wave MI, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.</description>
        <time_frame>From post-procedure to 6 months and 9 months follow-up</time_frame>
        <population>The number of participants who had sufficient follow-up or who had an event prior to the end of follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Percentages of Participants Who Experienced Any Target Vessel Failure (TVF) up to 6 and 9 Months Post-procedure</title>
          <description>TVF was defined as any Target vessel revascularization, Q wave or non-Q wave MI, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.</description>
          <population>The number of participants who had sufficient follow-up or who had an event prior to the end of follow-up.</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0" lower_limit="4.9" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 Months Post-Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" lower_limit="6.3" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Lumen Volume (mm3) at Post-procedure</title>
        <time_frame>At Post-procedure</time_frame>
        <population>The number of participants who had lumen volume data at post-procedure</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Average Lumen Volume (mm3) at Post-procedure</title>
          <population>The number of participants who had lumen volume data at post-procedure</population>
          <units>mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.34" spread="38.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Stent Obstruction Volume at Post-procedure</title>
        <description>Stent obstruction Volume equals 100 * [1-(lumen volume/baseline stent volume)]; usually this is equal to zero at baseline, since the stent is freshly implanted and no obstruction is expected</description>
        <time_frame>At post-procedure</time_frame>
        <population>Number of participants who had Stent Obstruction Volume data at post-procedure</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Average Stent Obstruction Volume at Post-procedure</title>
          <description>Stent obstruction Volume equals 100 * [1-(lumen volume/baseline stent volume)]; usually this is equal to zero at baseline, since the stent is freshly implanted and no obstruction is expected</description>
          <population>Number of participants who had Stent Obstruction Volume data at post-procedure</population>
          <units>mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Lumen Volume (mm3) at 6 Months Post-procedure</title>
        <time_frame>From post-procedure to 6 months</time_frame>
        <population>The number of participants who had Lumen Volume data at 6 months post-procedure</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Average Lumen Volume (mm3) at 6 Months Post-procedure</title>
          <population>The number of participants who had Lumen Volume data at 6 months post-procedure</population>
          <units>mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.25" spread="25.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Stent Obstruction Volume at 6 Months Post-procedure</title>
        <time_frame>From post-procedure to 6 months</time_frame>
        <population>The number of participants with Stent Obstruction Volume data at 6 months post-procedure</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Average Stent Obstruction Volume at 6 Months Post-procedure</title>
          <population>The number of participants with Stent Obstruction Volume data at 6 months post-procedure</population>
          <units>mm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Lesion Success at Post-procedure</title>
        <description>Lesion success defined as the attainment of &lt;50 percent residual stenosis (by QCA) using any percutaneous method</description>
        <time_frame>At post-procedure</time_frame>
        <population>Number of Participants without missing lesion success data</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Lesion Success at Post-procedure</title>
          <description>Lesion success defined as the attainment of &lt;50 percent residual stenosis (by QCA) using any percutaneous method</description>
          <population>Number of Participants without missing lesion success data</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" lower_limit="92.9" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Device Success at Post-procedure</title>
        <description>Device success was defined as achievement of a final residual diameter stenosis of less than 50 percent as measured by QCA, using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used</description>
        <time_frame>At post-procedure</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Device Success at Post-procedure</title>
          <description>Device success was defined as achievement of a final residual diameter stenosis of less than 50 percent as measured by QCA, using the assigned device only. If QCA is not available, the visual estimate of diameter stenosis is used</description>
          <population>All participants</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.0" lower_limit="90.1" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Procedure Success Before Hospital Discharge</title>
        <description>Procedure success defined as achievement of a final diameter stenosis of less than 50 percent (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay</description>
        <time_frame>From post-procedure to hospital discharge</time_frame>
        <population>Number of participants without missing procedure success data</population>
        <group_list>
          <group group_id="O1">
            <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
            <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Procedure Success Before Hospital Discharge</title>
          <description>Procedure success defined as achievement of a final diameter stenosis of less than 50 percent (by QCA) using any percutaneous method, without the occurrence of death, MI, or repeat revascularization of the target lesion during the hospital stay</description>
          <population>Number of participants without missing procedure success data</population>
          <units>Percentage of participants</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="91.4" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From post-procedure to 1440 days follow up</time_frame>
      <group_list>
        <group group_id="E1">
          <title>2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-exp Stent</title>
          <description>The 2.25mm Sirolimus-eluting Bx VELOCITY™ Balloon-expandable stent in patients with de novo native coronary artery lesions</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Total number of participants who died from post-procedure to 1440 days follow up.</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction (Q wave or Non-Q wave)</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Target Lesion Revascularization</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Target Vessel Revascularization not involving Target Lesion</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Target Vessel Revascularization (All)</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="95"/>
              </event>
              <event>
                <sub_title>Acute/Subacute Stent Thrombosis to 30 Days</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Late Stent Thrombosis (31-1440 Days)</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Subacute Closure</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident (CVA)</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Hemorrhagic Vascular Complications</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Target Vessel Failure</sub_title>
                <description>The number at risk is defined as the number of participants who had sufficient 4 years post-procedure follow-up or who had at least one event prior to the end of follow-up</description>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sidney Cohen, MD PhD, Vice President</name_or_title>
      <organization>Cordis</organization>
      <phone>650 614-2726</phone>
      <email>scohen7@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

